A Study of 3mg Once Every Two Weeks Administration of Efsubaglutide Alfa Injection in Type 2 Diabetes Patients.

PHASE2CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

December 18, 2024

Primary Completion Date

May 29, 2025

Study Completion Date

May 29, 2025

Conditions
Type2 Diabetes
Interventions
DRUG

Efsubaglutide Alfa Injection

Efsubaglutide Alfa 3mg/0.5ml

DRUG

Efsubaglutide Alfa Injection

Efsubaglutide Alfa 1mg/0.5ml

Trial Locations (10)

210008

Nanjing First Hospital, Nanjing

Unknown

CangZhou Hospital of Integrated TCM and Western Medicine in Hebei Province, Cangzhou

Huzhou Central Hospital, Huzhou

Jiangsu Province Offical Hospital, Nanjing

Ningbo First Hospital, Ningbo

Ningbo Medical Center Lihuili Hospital, Ningbo

The First Affiliated Hospital of Soochow University, Suzhou

The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou

Wenzhou Central Hospital, Wenzhou

Zibo Municipal Hospital, Zibo

All Listed Sponsors
lead

Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.

OTHER

NCT06849843 - A Study of 3mg Once Every Two Weeks Administration of Efsubaglutide Alfa Injection in Type 2 Diabetes Patients. | Biotech Hunter | Biotech Hunter